Florida may join the expanding list of states that are limiting third-party payers’ use of unnecessary fail first policies. Such…
The U.S. Food and Drug Administration (FDA) recently approved the first follow-on biologic (commonly referred to as “biosimilars”) and will…
Aimed Alliance Public Policy Director Stacey L. Worthy will be a keynote speaker at the Abuse Deterrent Formulations Summit, which…
Aimed Alliance Public Policy Director Stacey L. Worthy will present at the 46th annual American Society of Addiction Medicine Conference,…
Aimed Alliance’s Public Policy Director Stacey L. Worthy was honored to present at the fourth annual National Rx Drug Abuse…
This week, the U.S. Food and Drug Administration (FDA) issued new guidance on how pharmaceutical companies can change their Risk…
On April 9, 2015, The Hill published Glimmer of Hope in Reducing Prescription Drug Abuse, written by Michael Barnes, an…
Health care advocacy groups are arguing that uninsured women who become pregnant should be able to obtain health coverage at…
A comprehensive, broad research program dedicated to encouraging creative approaches to precision medicine is the next step the National Institutes…
On February 24, a federal judge struck down the Maine Pharmacy Act, which had allowed Maine residents to buy and…